Brenda Walker Griffin

Alcon (United States)

Papers

2

Total Citations

48

H-Index

2

About

Brenda Walker Griffin is a pioneering researcher in ocular pharmacology, with a primary focus on prostaglandin receptor signaling in the eye. Her work has significantly advanced the understanding of how prostaglandins regulate intraocular pressure, a critical factor in glaucoma treatment. Griffin’s most cited studies, including her 1998 paper on prostaglandin-stimulated adenylyl cyclase activity via the EP₂ receptor in human nonpigmented ciliary epithelial cells (26 citations), established the pharmacological identity of key receptors involved in aqueous humor dynamics. Her innovative use of a semi-automated, robotic radioimmunoassay to measure cAMP (22 citations) demonstrated a methodological breakthrough, enabling high-throughput analysis of DP, EP₂, and IP receptor activation across ocular and other cell types. These contributions have provided a foundational framework for developing targeted therapies for ocular hypertension and glaucoma. Griffin’s work is frequently cited in studies exploring prostaglandin analog mechanisms, underscoring its lasting impact on both basic science and clinical ophthalmology. Her dedication to precise receptor characterization continues to inspire researchers investigating G-protein-coupled receptor signaling in the eye.

Research Focus

Key Achievements

2
H-Index
2
Papers
48
Total Citations
24
Avg Citations/Paper
🏆 Most Cited Paper
Prostaglandin-Stimulated Adenylyl Cyclase Activity Via a Pharmacologically Defined EP <sub>2</sub> Receptor in Human Nonpigmented Ciliary Epithelial Cells
26 citations · 1998
📈 Most Prolific Year: 1998 (2 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Alcon (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago